Literature DB >> 3833240

Preparation and biomedical applications of bispecific antibodies.

H Paulus.   

Abstract

Bispecific antibodies are immunoglobulin molecules with two different antigen binding sites. They can be prepared either by chemical crosslinking of immunoglobulins with different antigen specificities or by reassortment of the polypeptide chains from two different immunoglobulins to produce hybrid molecules with dual specificity. None of the earlier methods for the preparation of bispecific antibodies assure molecular homogeneity without difficult purification procedures; recently, however, a facile and efficient method was developed which can yield pure bispecific antibodies from monoclonal antibody fragments. This new method avoids some of the problems encountered earlier by using arsenite as a dithiol complexing agent to prevent intramolecular disulfide formation and 5,5'-dithiobis (2-nitrobenzoic acid) as a thiol activating agent to effect the directed recombination of two different antibody half-molecules. Bispecific monoclonal antibodies thus obtained are useful heterobifunctional reagents on account of their ability to bind two different antigens in a uniquely defined spatial relationship. They have potential applications as agents for enzyme immobilization, in the assembly of enzyme electrodes and multienzyme complexes, as reagents for two-site and homogeneous immunoassays, as electron microscopy markers for subcellular structures, and as targeting agents for cytotoxic drugs. In many of these applications, bispecific monoclonal antibodies have fundamental advantages over the heterogeneous mixtures containing hybrid antibodies that were available in the past.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3833240

Source DB:  PubMed          Journal:  Behring Inst Mitt        ISSN: 0301-0457


  4 in total

Review 1.  Bispecific antibody: a tool for diagnosis and treatment of disease.

Authors:  S Songsivilai; P J Lachmann
Journal:  Clin Exp Immunol       Date:  1990-03       Impact factor: 4.330

2.  The bispecific anti-CD3 × anti-CD155 antibody mediates T cell immunotherapy for human prostate cancer.

Authors:  Huijun Zhao; Juan Ma; Ting Lei; Wanru Ma; Man Zhang
Journal:  Invest New Drugs       Date:  2018-10-29       Impact factor: 3.850

Review 3.  Antibody mediated targeting of radioisotopes, drugs and toxins in diagnosis and treatment.

Authors:  C H Ford; V J Richardson; V S Reddy
Journal:  Indian J Pediatr       Date:  1990 Jan-Feb       Impact factor: 1.967

4.  Development of a bispecific monoclonal antibody against a gallium-67 chelate and the human melanoma-associated antigen p97 for potential use in pretargeted immunoscintigraphy.

Authors:  C Somasundaram; S Matzku; J Schuhmacher; M Zöller
Journal:  Cancer Immunol Immunother       Date:  1993-05       Impact factor: 6.968

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.